A 24-month updated analysis of the comparative effectiveness of ZUMA-5 (axi-cel) vs. SCHOLAR-5 external control in relapsed/refractory follicular lymphoma.
Maria Lia PalombaPaola GhioneAnik R PatelMyrna NahasSara BeygiAnthony J HatswellSteve KantersEve H Limbrick-OldfieldSally W WadeMarkqayne D RayJessica OwenSattva S NeelapuJohn GribbenJohn RadfordSabela BobilloPublished in: Expert review of anticancer therapy (2023)
This updated analysis, using a longer minimum follow-up than a previously published analysis, shows that the improved efficacy of axi-cel, relative to available therapies, in r/r FL is durable. .